Hikal Ltd. Reports 10% YoY Growth in Q3 FY26 Revenue, Improves EBITDA Margin

Hikal Ltd., a preferred long-term partner for leading global life sciences companies, announced its unaudited financial results for the quarter and nine months ended 31st December 2025. The company reported a YoY growth of 10% in revenue to 2 494 crores and a 15% growth in EBITDA to 283 crores. The EBITDA margin improved by 70 bps on a YoY basis to 16.8%. The Pharmaceuticals business witnessed a recovery in Sales in Q3, mitigating the impact of sales deferrals seen in H1 due to regulatory developments. The crop protection business registered growth over previous quarters and the same period last year, supported by the development of a strong future pipeline and a continued focus on maximizing capacity utilization and improving operational efficiency. The company also strengthened its balance sheet and improved its debt-equity ratio to 0.58x.